FDA Brief

Warning letters Food

FDA warning letter to

Natural Ginger, Corp/Jonaus Corp

MediumIssued Jun 25, 2024Posted Jul 9, 2024Division of Human and Animal Food Operations East IV

FDA warned Natural Ginger that it markets six syrups and supplements as unapproved new drugs with disease-treatment claims on its website.

What happened

In June 2024, FDA reviewed www.naturgin.com and a linked Facebook page and found product pages and a February 25, 2021 Facebook post claiming the syrups and supplements treat or prevent colds, flu, cough, sore throat, headaches, and infections. FDA said these claims make the products drugs, but they are not generally recognized as safe and effective for those uses and lack FDA approval. FDA also said the children's syrup and adult forte syrup lack adequate directions because their intended uses require a licensed practitioner.

What FDA found

  1. FDA found website and Facebook claims that the products cure, mitigate, treat, or prevent diseases, so the products are intended for use as drugs.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 321(g)(1)(B)]
  2. The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and have no FDA approval.

    sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The children's syrup and adult forte syrup are misbranded because they lack adequate directions for use for diseases that require a licensed practitioner.

    section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA says introducing or delivering the misbranded drugs into interstate commerce violates the Act.

    section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations and prevent recurrence, with supporting documents. If the company cannot complete the actions in that time, it must state the reason for delay and when it will finish; if it disagrees, it must give its reasoning and supporting information.

Who should pay attention

  • retailers and online marketplaces selling Naturgin products
  • supplement brands making disease-treatment claims on websites or social media
  • companies selling children's cough or cold remedies as dietary supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk